These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7554552)

  • 1. Methotrexate: the agent of choice for chronic inflammatory disorders. A perspective ten years later.
    Gutiérrez-Ureña S; Espinoza LR
    Clin Exp Rheumatol; 1995; 13(3):281-4. PubMed ID: 7554552
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms of action of methotrexate.
    Chan ES; Cronstein BN
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S5-8. PubMed ID: 24219035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of methotrexate in childhood rheumatic diseases.
    Wallace CA
    Arthritis Rheum; 1998 Mar; 41(3):381-91. PubMed ID: 9506564
    [No Abstract]   [Full Text] [Related]  

  • 4. Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists.
    Gossec L; Bijlsma JW; Bombardier C; Canhão H; Devlin J; Edwards CJ; Hamuryudan V; Kvien TK; Leeb BF; Martín-Mola EM; Mielants H; Müller-Ladner U; Ostergaard M; Pereira IA; Ramos-Remus C; Zochling J; Dougados M
    Ann Rheum Dis; 2011 Feb; 70(2):388-9. PubMed ID: 20472594
    [No Abstract]   [Full Text] [Related]  

  • 5. Toward a better understanding of methotrexate.
    Kremer JM
    Arthritis Rheum; 2004 May; 50(5):1370-82. PubMed ID: 15146406
    [No Abstract]   [Full Text] [Related]  

  • 6. [The use of methotrexate in rheumatology: results and prospects].
    Nasonov EL
    Klin Med (Mosk); 1996; 74(5):10-5. PubMed ID: 8999172
    [No Abstract]   [Full Text] [Related]  

  • 7. [Current status of methotrexate].
    Fiehn C
    Z Rheumatol; 2011 Feb; 70(2):99-100. PubMed ID: 21312022
    [No Abstract]   [Full Text] [Related]  

  • 8. Methotrexate--the anchor drug--an introduction.
    Pincus T; Cronstein B; Braun J
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S1-2. PubMed ID: 21044424
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacogenetics in the rheumatic diseases, from prêt-à-porter to haute couture.
    Cronstein BN
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):2-3. PubMed ID: 16932642
    [No Abstract]   [Full Text] [Related]  

  • 10. Methotrexate for maintenance of remission in IgG4-related disease.
    Della-Torre E; Campochiaro C; Bozzolo EP; Dagna L; Scotti R; Nicoletti R; Stone JH; Sabbadini MG
    Rheumatology (Oxford); 2015 Oct; 54(10):1934-6. PubMed ID: 26139657
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.
    Bjornsson AH; Grondal G; Kristjansson M; Jonsdottir T; Love TJ; Gudbjornsson B;
    Ann Rheum Dis; 2021 May; 80(5):671-672. PubMed ID: 33402343
    [No Abstract]   [Full Text] [Related]  

  • 12. Methotrexate and long-term treatment of rheumatic disease: comment on the article by Kremer.
    Ranganathan P; McLeod HL
    Arthritis Rheum; 2005 Feb; 52(2):670-1; author reply 672. PubMed ID: 15692997
    [No Abstract]   [Full Text] [Related]  

  • 13. Methotrexate induced lymphoma?
    Bleyer WA
    J Rheumatol; 1998 Mar; 25(3):404-7. PubMed ID: 9517755
    [No Abstract]   [Full Text] [Related]  

  • 14. Why is methotrexate the first selection in disease-modifying antirheumatic drug therapy? Comment on the article by Wolfe et al.
    Caballero-Uribe CV
    Arthritis Care Res; 1999 Apr; 12(2):152. PubMed ID: 10513503
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current "off label use" of methotrexate for chronic inflammatory rheumatic diseases].
    Briem S; Lorenz HM
    Z Rheumatol; 2011 Feb; 70(2):123-8. PubMed ID: 21267732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Trends in the treatment of rheumatic diseases].
    Trotta F; Padovan M
    Recenti Prog Med; 1999 Oct; 90(10):510-4. PubMed ID: 10592735
    [No Abstract]   [Full Text] [Related]  

  • 17. The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
    Maini RN
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv106-8. PubMed ID: 16239377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of transaminase elevation during concomitant methotrexate and isoniazid therapy.
    Ekochin LH; Manadan AM; Aggarwal R; Sequeira W; Block JA
    J Rheumatol; 2009 Sep; 36(9):2127. PubMed ID: 19738229
    [No Abstract]   [Full Text] [Related]  

  • 19. Evidence-based recommendations for treatment with methotrexate in rheumatic disorders.
    Madsen OR; Faurschou M; Loft AG; Sørensen IJ; Knudsen JB; Baslund B; Hansen A; Hansen MS; Østergaard M
    Dan Med Bull; 2010 Oct; 57(10):A4190. PubMed ID: 21040680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical treatment of adolescents with rheumatic disease.
    Hollister JR
    Adolesc Med; 1998 Feb; 9(1):163-70, vii. PubMed ID: 10961259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.